End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, H1 2018 - ResearchAndMarkets.com

DUBLIN--()--The "End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.

The pipeline guide provides a snapshot of the global therapeutic landscape of End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genito Urinary System And Sex Hormones).

The pipeline guide reviews pipeline therapeutics for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genito Urinary System And Sex Hormones).

Companies Mentioned

  • CTI BioPharma Corp
  • Novartis AG
  • Prolong Pharmaceuticals LLC
  • VESSL Therapeutics Ltd

Key Topics Covered

  1. Introduction
  2. Report Coverage
  3. End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Overview
  4. End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Therapeutics Development
  5. Pipeline Overview
  6. Pipeline by Companies
  7. Products under Development by Companies
  8. End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Therapeutics Assessment
  9. Assessment by Target
  10. Assessment by Mechanism of Action
  11. Assessment by Route of Administration
  12. Assessment by Molecule Type
  13. End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Companies Involved in Therapeutics Development
  14. CTI BioPharma Corp
  15. Novartis AG
  16. Prolong Pharmaceuticals LLC
  17. VESSL Therapeutics Ltd
  18. End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Drug Profiles
  19. Cell Therapy for Peripheral Arterial Disease and End-Stage Kidney Disease - Drug Profile
  20. Product Description
  21. Mechanism Of Action
  22. R&D Progress
  23. pacritinib - Drug Profile
  24. Product Description
  25. Mechanism Of Action
  26. R&D Progress
  27. Recombinant Plasma Gelsolin Replacement for Renal Disease - Drug Profile
  28. Product Description
  29. Mechanism Of Action
  30. R&D Progress
  31. Sanguinate - Drug Profile
  32. Product Description
  33. Mechanism Of Action
  34. R&D Progress
  35. tesidolumab - Drug Profile
  36. Product Description
  37. Mechanism Of Action
  38. R&D Progress
  39. End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Dormant Projects
  40. End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Discontinued Products
  41. Appendix
  42. Methodology
  43. Coverage
  44. Secondary Research
  45. Primary Research
  46. Expert Panel Validation

For more information about this report visit https://www.researchandmarkets.com/research/pcvmhb/endstage_kidney?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Liver and Kidney Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Liver and Kidney Disorders Drugs